查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822387

2032 年梅毒檢測市場預測：按類型、檢測地點、技術、分銷管道、應用、最終用戶和地區進行的全球分析

Syphilis Testing Market Forecasts to 2032 - Global Analysis By Type, Location of Testing, Technology, Distribution Channel, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球梅毒檢測市場預計在 2025 年達到 24.9 億美元，預計到 2032 年將達到 44.9 億美元，預測期內的複合年成長率為 8.8%。

梅毒檢測是指旨在識別梅毒螺旋體（一種導致梅毒的細菌）感染的臨床程序。診斷方法通常包括血液非梅毒螺旋體檢測和梅毒螺旋體檢測，有助於確定疾病分期、確診感染並追蹤患者對治療的反應。此類檢測對於限制疾病傳播、保護母嬰健康以及控制併發症至關重要。對於高風險族群或可能感染性行為感染傳染病的族群，此類檢測尤其重要。

增加常規篩檢項目

梅毒篩檢的日益常規化實施極大地推動了市場需求。公共衛生機構正在加強，以儘早發現感染，尤其是在孕婦和愛滋病毒陽性者等高風險族群。快速就地檢驗技術的進步使其能夠在診所和推廣機構中廣泛部署。與數位健康平台的整合正在簡化患者追蹤和診斷跟進。新興趨勢包括基於人工智慧的篩檢演算法和基於行動裝置的檢測套組，從而提高了可及性。隨著各國政府擴大其性傳染感染監測項目，梅毒檢測正成為預防性醫療保健策略的核心部分。

醫療基礎設施和醫療服務不足

許多低收入國家面臨訓練有素的人員、檢測能力和基本檢測用品短缺的問題。基礎設施缺口在孕產婦保健機構特別明顯，而早期發現先天性梅毒至關重要。數位連結性的缺乏進一步限制了與集中式衛生系統的整合。行動診所和遠端醫療提供了部分解決方案，但擴充性仍是一項挑戰。如果沒有對醫療基礎設施的持續投資，梅毒檢測覆蓋率在各地區仍將不平衡。

整合多重和雙重用途測試

在臨床和公共衛生領域，能夠同時檢測多種性傳染感染的雙效檢測方法正變得越來越普遍。這些平台縮短了周轉時間，提高了成本效益，並增強了病患的依從性。微流體和生物感測器技術的進步使得緊湊型多分析物檢測設備能夠實現分散式使用。監管機構擴大支持批量檢測通訊協定，以簡化醫療服務。隨著個人化醫療的發展，多重梅毒檢測預計將在全面的性健康篩檢中發揮關鍵作用。

與其他性傳染感染診斷的競爭

HIV、披衣菌感染和淋病檢測通常佔據採購預算和公共衛生優先事項的主導地位。除非多病原體檢測組合能夠策略性地整合，否則對梅毒專案創新的關注可能會減少。分子診斷和基於 CRISPR 的檢測技術的快速發展正在將人們的注意力轉移到新技術上。市場碎片化也受到地區對特定檢測形式和品牌的偏好所驅動。

COVID-19的影響

疫情擾亂了常規性傳染感染篩檢項目，導致診斷延遲和檢測減少。封鎖措施以及將資源重新分配給新冠診斷工具，導致實驗室能力和供應鏈緊張。然而，這場危機加速了遠端性傳染感染檢測套組和數位報告平台的採用。緊急監管措施使得新型梅毒檢測（包括自我檢測）得以快速核准。疫情後策略如今強調韌性、分散式診斷以及與疫情防範框架的整合。

預測期內，先天性梅毒市場預計將佔最大佔有率

由於先天性梅毒對公共衛生有重大影響，預計將在預測期內佔據最大的市場佔有率。強制性孕產婦篩檢和產前護理通訊協定的改進正在推動對早期檢測工具的需求。快速梅毒螺旋體檢測技術的進步使得在懷孕期間及時介入成為可能。各國政府正透過有針對性的資金和監測計畫優先消除先天性梅毒。與電子健康記錄的整合正在改善病例追蹤和後續治療。隨著人們意識的提高，先天性梅毒檢測正成為孕產婦和新生兒健康策略的基石。

預計預測期內公共衛生計畫部分將以最高的複合年成長率成長。

受全球性傳播感染控制舉措擴展的推動，公共衛生計畫領域預計將在預測期內實現最高成長率。國家和地方的宣傳活動正在透過流動單位、社區推廣和學校干預措施擴大梅毒篩檢。雲端基礎數據系統的採用正在增強專案監測和流行病學洞察。低成本、高通量檢測平台的創新使大規模篩檢更加可行。非政府組織、政府和診斷公司之間的夥伴關係正在加速在高負擔地區的部署。隨著全球衛生重點轉向消除性傳染感染，公共衛生計畫將成為市場擴張的中心。

比最大的地區

預計亞太地區將在預測期內佔據最大市場佔有率，這得益於醫療保健投資的增加和全民篩檢工作的推進。中國、印度和印尼等國家正在透過國家衛生任務和數位健康部署擴大性傳染感染診斷服務。檢測套組的本地化生產正在提高可負擔性和供應鏈的韌性。新興趨勢包括人工智慧驅動的診斷平台和專為偏遠地區量身定做的行動檢測實驗室。全球和區域公司之間的策略合作夥伴關係正在增強技術轉移和市場滲透。

複合年成長率最高的地區：

在技​​術領先地位和強大的公共衛生基礎設施的推動下，北美預計將在預測期內呈現最高的複合年成長率。美國和加拿大正大力投資下一代性傳染感染診斷技術，包括分子和人工智慧增強平台。監管機構正在簡化創新梅毒檢測的核准，包括居家醫療和遠端醫療檢測。與電子健康記錄和預測分析的整合正在改善個案管理和疫情應對。保險報銷框架越來越支持常規性傳染感染篩檢，尤其是在醫療資源匱乏的社區。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球梅毒檢測市場類型

  • 一期梅毒
  • 二期梅毒
  • 先天性梅毒
  • 潛伏梅毒
  • 其他類型

6. 全球梅毒檢測市場（依檢測地點分類）

  • 實驗室檢測
  • 在家測試
  • 就地檢驗

7. 全球梅毒檢測市場（按技術）

  • 免疫檢測
  • 分子診斷
  • 復用平台
  • 其他技術

8. 全球梅毒檢測市場（依分銷管道）

  • 直銷
  • 網路藥局
  • 零售藥局

9. 全球梅毒檢測市場（按應用）

  • 醫院
  • 診所
  • 公共衛生項目
  • 診斷實驗室
  • 其他用途

第 10 章全球梅毒檢測市場（以最終用戶分類）

  • 公共醫療機構
  • 私人醫療機構
  • 非政府組織和社區健康中心
  • 其他最終用戶

第 11 章。全球梅毒檢測市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Abbott Laboratories
  • SD Biosensor
  • Roche Diagnostics
  • Trinity Biotech
  • Siemens Healthineers
  • MedMira Inc.
  • Thermo Fisher Scientific
  • Fujirebio
  • Bio-Rad Laboratories
  • QuidelOrtho Corporation
  • Danaher Corporation
  • bioMerieux
  • Becton, Dickinson and Company（BD）
  • OraSure Technologies
  • Hologic Inc.
Product Code: SMRC31141

According to Stratistics MRC, the Global Syphilis Testing Market is accounted for $2.49 billion in 2025 and is expected to reach $4.49 billion by 2032 growing at a CAGR of 8.8% during the forecast period. Syphilis testing refers to clinical procedures aimed at identifying infection caused by Treponema pallidum, the bacterium that leads to syphilis. Diagnostic methods typically include blood-based non-treponemal and treponemal tests, which help determine disease stage, verify infection, and track patient response to treatment. This testing is vital for reducing disease spread, protecting maternal and infant health, and managing complications. It is particularly significant for individuals at higher risk or with possible exposure to sexually transmitted infections.

Market Dynamics:

Driver:

Increased routine screening programs

The rising implementation of routine syphilis screening initiatives is significantly boosting market demand. Public health agencies are intensifying efforts to detect infections early, especially among high-risk populations such as pregnant women and individuals with HIV. Technological advancements in rapid point-of-care tests are enabling broader deployment across clinics and outreach settings. Integration with digital health platforms is streamlining patient tracking and follow-up diagnostics. Emerging trends include AI-assisted screening algorithms and mobile-based testing kits that improve accessibility. As governments expand STI surveillance programs, syphilis testing is becoming a core component of preventive healthcare strategies.

Restraint:

Inadequate healthcare infrastructure and access

Many low-income countries face shortages in trained personnel, laboratory capacity, and essential testing supplies. Infrastructure gaps are especially pronounced in antenatal care settings, where early detection of congenital syphilis is critical. The lack of digital connectivity further restricts integration with centralized health systems. While mobile clinics and telemedicine offer partial solutions, scalability remains a challenge. Without sustained investment in healthcare infrastructure, syphilis testing coverage will remain uneven across geographies.

Opportunity:

Integration of multiplex and dual-purpose tests

Dual-purpose assays that detect multiple STIs simultaneously are gaining traction in both clinical and public health settings. These platforms reduce turnaround time, improve cost-efficiency, and enhance patient compliance. Advances in microfluidics and biosensor technologies are enabling compact, multi-analyte devices suitable for decentralized use. Regulatory bodies are increasingly supporting bundled testing protocols to streamline care delivery. As personalized medicine evolves, multiplex syphilis tests are expected to play a pivotal role in integrated sexual health diagnostics.

Threat:

Competition from other STI diagnostics

Tests for HIV, chlamydia, and gonorrhea often dominate procurement budgets and public health priorities. Multi-pathogen panels may dilute focus on syphilis-specific innovations unless bundled strategically. Rapid developments in molecular diagnostics and CRISPR-based detection are shifting attention toward newer technologies. Market fragmentation is also driven by regional preferences for certain test formats or brands.

Covid-19 Impact

The pandemic disrupted routine STI screening programs, leading to delayed diagnoses and reduced testing volumes. Lockdowns and resource reallocation toward Covid-19 diagnostics strained laboratory capacity and supply chains. However, the crisis accelerated adoption of remote testing kits and digital reporting platforms for STIs. Emergency regulatory pathways enabled faster approval of novel syphilis assays, including self-testing formats. Post-pandemic strategies now emphasize resilience, decentralized diagnostics, and integration with pandemic preparedness frameworks.

The congenital syphilis segment is expected to be the largest during the forecast period

The congenital syphilis segment is expected to account for the largest market share during the forecast period, due to its critical public health implications. Rising maternal screening mandates and improved prenatal care protocols are driving demand for early detection tools. Technological advances in rapid treponemal tests are enabling timely intervention during pregnancy. Governments are prioritizing congenital syphilis elimination through targeted funding and surveillance programs. Integration with electronic health records is improving case tracking and follow-up treatment. As awareness grows, congenital syphilis testing is becoming a cornerstone of maternal and neonatal health strategies.

The public health programs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the public health programs segment is predicted to witness the highest growth rate, driven by expanding STI control initiatives worldwide. National and regional campaigns are scaling up syphilis screening through mobile units, community outreach, and school-based interventions. Adoption of cloud-based data systems is enhancing program monitoring and epidemiological insights. Innovations in low-cost, high-throughput testing platforms are making mass screening more feasible. Partnerships between NGOs, governments, and diagnostic firms are accelerating deployment in high-burden areas. As global health priorities shift toward STI elimination, public health programs will be central to market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and population-wide screening efforts. Countries like China, India, and Indonesia are scaling up STI diagnostics through national health missions and digital health rollouts. Local manufacturing of test kits is improving affordability and supply chain resilience. Emerging trends include AI-powered diagnostic platforms and mobile testing labs tailored for remote regions. Strategic collaborations between global and regional players are enhancing technology transfer and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological leadership and robust public health infrastructure. The U.S. and Canada are investing heavily in next-gen STI diagnostics, including molecular and AI-enhanced platforms. Regulatory agencies are streamlining approvals for innovative syphilis tests, including home-based and telehealth-compatible formats. Integration with electronic medical records and predictive analytics is improving case management and outbreak response. Reimbursement frameworks are increasingly supportive of routine STI screening, especially in underserved communities.

Key players in the market

Some of the key players profiled in the Syphilis Testing Market include Abbott Laboratories, SD Biosensor, Roche Diagnostics, Trinity Biotech, Siemens Healthineers, MedMira Inc., Thermo Fisher Scientific, Fujirebio, Bio-Rad Laboratories, QuidelOrtho Corporation, Danaher Corporation, bioMerieux, Becton, Dickinson and Company (BD), OraSure Technologies, and Hologic Inc.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Types Covered:

  • Primary Syphilis
  • Secondary Syphilis
  • Congenital Syphilis
  • Latent Syphilis
  • Other Types

Location of Testings Covered:

  • Laboratory-Based Testing
  • Home-Based Testing
  • Point-of-Care Testing

Technologies Covered:

  • Immunoassay
  • Molecular Diagnostics
  • Multiplex Platforms
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Hospitals
  • Clinics
  • Public Health Programs
  • Diagnostic Laboratories
  • Other Applications

End Users Covered:

  • Public Healthcare Facilities
  • Private Healthcare Providers
  • NGOs and Community Health Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Syphilis Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Primary Syphilis
  • 5.3 Secondary Syphilis
  • 5.4 Congenital Syphilis
  • 5.5 Latent Syphilis
  • 5.6 Other Types

6 Global Syphilis Testing Market, By Location of Testing

  • 6.1 Introduction
  • 6.2 Laboratory-Based Testing
  • 6.3 Home-Based Testing
  • 6.4 Point-of-Care Testing

7 Global Syphilis Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Immunoassay
  • 7.3 Molecular Diagnostics
  • 7.4 Multiplex Platforms
  • 7.5 Other Technologies

8 Global Syphilis Testing Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Online Pharmacies
  • 8.4 Retail Pharmacies

9 Global Syphilis Testing Market, By Application

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Public Health Programs
  • 9.5 Diagnostic Laboratories
  • 9.6 Other Applications

10 Global Syphilis Testing Market, By End User

  • 10.1 Introduction
  • 10.2 Public Healthcare Facilities
  • 10.3 Private Healthcare Providers
  • 10.4 NGOs and Community Health Centers
  • 10.5 Other End Users

11 Global Syphilis Testing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 SD Biosensor
  • 13.3 Roche Diagnostics
  • 13.4 Trinity Biotech
  • 13.5 Siemens Healthineers
  • 13.6 MedMira Inc.
  • 13.7 Thermo Fisher Scientific
  • 13.8 Fujirebio
  • 13.9 Bio-Rad Laboratories
  • 13.10 QuidelOrtho Corporation
  • 13.11 Danaher Corporation
  • 13.12 bioMerieux
  • 13.13 Becton, Dickinson and Company (BD)
  • 13.14 OraSure Technologies
  • 13.15 Hologic Inc.

List of Tables

  • Table 1 Global Syphilis Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Syphilis Testing Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Syphilis Testing Market Outlook, By Primary Syphilis (2024-2032) ($MN)
  • Table 4 Global Syphilis Testing Market Outlook, By Secondary Syphilis (2024-2032) ($MN)
  • Table 5 Global Syphilis Testing Market Outlook, By Congenital Syphilis (2024-2032) ($MN)
  • Table 6 Global Syphilis Testing Market Outlook, By Latent Syphilis (2024-2032) ($MN)
  • Table 7 Global Syphilis Testing Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 8 Global Syphilis Testing Market Outlook, By Location of Testing (2024-2032) ($MN)
  • Table 9 Global Syphilis Testing Market Outlook, By Laboratory-Based Testing (2024-2032) ($MN)
  • Table 10 Global Syphilis Testing Market Outlook, By Home-Based Testing (2024-2032) ($MN)
  • Table 11 Global Syphilis Testing Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 12 Global Syphilis Testing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global Syphilis Testing Market Outlook, By Immunoassay (2024-2032) ($MN)
  • Table 14 Global Syphilis Testing Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
  • Table 15 Global Syphilis Testing Market Outlook, By Multiplex Platforms (2024-2032) ($MN)
  • Table 16 Global Syphilis Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 17 Global Syphilis Testing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 18 Global Syphilis Testing Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 19 Global Syphilis Testing Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 20 Global Syphilis Testing Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 21 Global Syphilis Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Syphilis Testing Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Syphilis Testing Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 24 Global Syphilis Testing Market Outlook, By Public Health Programs (2024-2032) ($MN)
  • Table 25 Global Syphilis Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 26 Global Syphilis Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 27 Global Syphilis Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Syphilis Testing Market Outlook, By Public Healthcare Facilities (2024-2032) ($MN)
  • Table 29 Global Syphilis Testing Market Outlook, By Private Healthcare Providers (2024-2032) ($MN)
  • Table 30 Global Syphilis Testing Market Outlook, By NGOs and Community Health Centers (2024-2032) ($MN)
  • Table 31 Global Syphilis Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.